Deal Watch: Merck KGAA Boosts Pharma Unit’s Reach And Capabilities With Sigma-Aldrich Buy

Acorda buys Civitas and its Parkinson’s candidate for $525 million, ending the latter’s intent to go public. Pharmacyclics and Servier unwind their 2009 agreement to co-develop oncology drug abexinostat.